Granicip

Product Description

Granicip is a pharmaceutical formulation containing the active component Granisetron. Manufactured by Cipla Ltd, this antiemetic agent is primarily indicated for the prevention of chemotherapy-induced and radiotherapy-induced nausea and vomiting.

Uses

Granicip is clinically prescribed for the prophylaxis and management of nausea and vomiting associated with oncological treatments including chemotherapy and radiation therapy. Additionally, it is utilized for preventing postoperative nausea and vomiting (PONV).

How to Use

Administer this medication orally as prescribed by your physician, typically one hour prior to chemotherapy administration or within one hour preceding surgical procedures. Dosage should be individualized based on clinical assessment and therapeutic response.

Mechanism of Action

Granicip exerts its therapeutic effect through selective antagonism of serotonin (5-HT3) receptors in the central nervous system. By inhibiting the action of serotonin released during cytotoxic therapy, it effectively prevents the initiation of the vomiting reflex.

Therapeutic Benefits

The principal therapeutic advantage of Granicip lies in its efficacy in preventing and controlling emesis associated with antineoplastic therapies and surgical interventions. This enhances patient comfort and compliance during treatment regimens and postoperative recovery.

Adverse Effects

Common adverse reactions may include cephalalgia, constipation, and abdominal discomfort. Persistent or worsening symptoms should be reported to healthcare providers. Although uncommon, serotonin syndrome represents a potentially serious complication requiring immediate medical attention.

Dosage and Administration

The standard adult dosage regimen consists of one tablet administered orally one hour prior to chemotherapy. For surgical prophylaxis, one tablet should be taken within one hour before anesthesia induction. Strict adherence to prescribing physician’s instructions is imperative.

Precautions

Prior to initiation of therapy, disclose any history of hypersensitivity reactions to granisetron or related compounds. Pregnancy should be considered when prescribing, with use restricted to cases where potential benefits outweigh risks under medical supervision.

Storage Conditions

Maintain Granicip tablets at controlled room temperature (20-25°C) in a dry environment protected from light exposure. Secure storage away from pediatric and animal access is mandatory. Properly dispose of expired or unused medication according to local regulations.